Ibuprofen sodium (Synonyms: (±)-Ibuprofen sodium) |
カタログ番号GC66211 |
イブプロフェン ((±)-イブプロフェン) ナトリウムは、13 μ の IC50 値を持つ経口活性の選択的 COX-1 阻害剤です;M.イブプロフェン ナトリウムは、細胞増殖、血管新生を阻害し、細胞アポトーシスを誘導します。イブプロフェン ナトリウムは、非ステロイド性抗炎症剤であり、一酸化窒素 (NO) 供与体です。イブプロフェン ナトリウムは、痛み、腫れ、炎症、感染症、免疫学、癌の研究に使用できます。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 31121-93-4
Sample solution is provided at 25 µL, 10mM.
Ibuprofen ((±)-Ibuprofen) sodium is an orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen sodium inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen sodium is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen sodium can be used in the research of pain, swelling, inflammation, infection, immunology, cancers[1][2][5][8].
Ibuprofen sodium (24 h) inhibits COX-1 and COX-2 activity with IC50 values of 13 μM and 370 μM[1].
Ibuprofen sodium (500 μM, 48 h) inhibits cell proliferation and angiogenesis, and induces apoptosis in AGS cells (Adenocarcinoma gastric cell line)[2].
Ibuprofen sodium (500 μM, 48 h) downregulates transcription of Akt, VEGF-A, PCNA, Bcl2, OCT3/4 and CD44 genes, but upregulates RNA levels of wild type P53 and Bax genes in AGS cell[2].
Ibuprofen sodium (500 μM, 24 h) restores microtubule reformation, microtubule-dependent intracellular cholesterol transport, and induces extension of microtubules to the cell periphery in both cystic fibrosis (CF) cell models and primary CF nasal epithelial cells[3].
Ibuprofen sodium (500 μM, 24 h) enhances UV-induced cell death in MCF-7 cells and MDA-MB-231 cells by a photosensitization process[4].
Cell Viability Assay[2]
Cell Line: | AGS cells |
Concentration: | 100-1000 μM |
Incubation Time: | 24 h, 48 h |
Result: | Inhibited AGS cell viability with IC50 values of 630 μM (trypan blue staining, 24 h), 456 μM (neutral red assay, 24 h), 549 μM (trypan blue staining , 48 h) and 408 μM (neutral red assay, 48 h). |
Ibuprofen sodium (fed in animal feedings, 300 mg/kg, 14 days) reduces overall tumor growth and enhances anti-tumor immune characteristics without adverse autoimmune reactions in a model of postpartum breast cancer[5].
Ibuprofen sodium (subcutaneous injection, 60 mg/kg, every second day for 15 days) reduces the risk of neuropathy in a rat model of chronic Oxaliplatin?induced peripheral neuropathy[6].
Ibuprofen sodium (oral administration, 20 mg/kg, every 12 hours, 5 doses total) decreases muscle growth (average muscle fiber cross-sectional area) without affecting regulation of supraspinatus tendon adaptions to exercise[7].
Ibuprofen sodium (oral administration, 35 mg/kg, twice daily) attenuates the Inflammatory response to pseudomonas aeruginosa in a rat model of chronic pulmonary infection[8].
Animal Model: | Syngeneic (D2A1) orthotopic Balb/c mouse model of PPBC (postpartum)[5] |
Dosage: | 300 mg/kg, daily for 14 days |
Administration: | Fed in animal feedings (added to pulverized standard chow and mixed dry, then mixed with water, made into chow pellets and dried thoroughly) |
Result: | Suppresed tumor growth, reduced presence of immature monocytes and increased numbers of T cells. Enhanced Th1 associated cytokines as well as promoted tumor border accumulation of T cells. |
Animal Model: | Oxaliplatin?induced peripheral neuropathy[6] |
Dosage: | 60 mg/kg, every second day for 15 days |
Administration: | Subcutaneous injection |
Result: | Lowered sensory nerve conduction velocity (SNCV). |
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *